BR112022007651A2 - Dispositivo de distribuição transdérmica de tetrabenazina - Google Patents
Dispositivo de distribuição transdérmica de tetrabenazinaInfo
- Publication number
- BR112022007651A2 BR112022007651A2 BR112022007651A BR112022007651A BR112022007651A2 BR 112022007651 A2 BR112022007651 A2 BR 112022007651A2 BR 112022007651 A BR112022007651 A BR 112022007651A BR 112022007651 A BR112022007651 A BR 112022007651A BR 112022007651 A2 BR112022007651 A2 BR 112022007651A2
- Authority
- BR
- Brazil
- Prior art keywords
- tetrabenazine
- transdermal delivery
- delivery device
- delivery
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
DISPOSITIVO DE DISTRIBUIÇÃO TRANSDÉRMICA DE TETRABENAZINA. Neste documento, são fornecidas composições, dispositivos de distribuição e métodos relacionados à distribuição de tetrabenazina e/ou tetrabenazina deuterada, por exemplo, distribuição contínua ou substancialmente contínua, tal como distribuição transdérmica, para o tratamento de um distúrbio de movimento hipercinético. Também são fornecidos dispositivos de distribuição transdérmica compreendendo tetrabenazina, uma tetrabenazina deuterada ou uma combinação destas composições farmacêuticas compreendendo tetrabenazina e/ou uma tetrabenazina deuterada, métodos de preparação das mesmas e métodos de uso das mesmas, por exemplo, para o tratamento de um distúrbio de movimento hipercinético.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924325P | 2019-10-22 | 2019-10-22 | |
| PCT/US2020/056559 WO2021081022A1 (en) | 2019-10-22 | 2020-10-21 | Tetrabenazine transdermal delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007651A2 true BR112022007651A2 (pt) | 2022-07-12 |
Family
ID=75619484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007651A BR112022007651A2 (pt) | 2019-10-22 | 2020-10-21 | Dispositivo de distribuição transdérmica de tetrabenazina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362165A1 (pt) |
| EP (1) | EP4048268A4 (pt) |
| JP (1) | JP2023500606A (pt) |
| KR (1) | KR20220104705A (pt) |
| CN (1) | CN114828851A (pt) |
| AU (1) | AU2020370073A1 (pt) |
| BR (1) | BR112022007651A2 (pt) |
| CA (1) | CA3158407A1 (pt) |
| IL (1) | IL292405A (pt) |
| MX (1) | MX2022004827A (pt) |
| TW (1) | TW202128164A (pt) |
| WO (1) | WO2021081022A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023026160A2 (pt) * | 2021-06-30 | 2024-03-05 | Neurocrine Biosciences Inc | Valbenazina para uso no tratamento de discinesia devido à paralisia cerebral |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200628175A (en) * | 2004-10-08 | 2006-08-16 | Noven Pharma | Transdermal drug delivert device including an occlusive backing |
| WO2006053067A2 (en) * | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| US9682068B2 (en) * | 2013-05-20 | 2017-06-20 | Mylan Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
| DK3265085T3 (da) * | 2015-03-06 | 2022-10-03 | Auspex Pharmaceuticals Inc | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser |
| EP3338768B1 (en) * | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
| GB2565049B (en) * | 2017-07-27 | 2020-06-10 | Reckitt Benckiser Health Ltd | A head assembly of a dermaplaning device |
| AU2019261403A1 (en) * | 2018-04-25 | 2020-11-12 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
-
2020
- 2020-10-21 CN CN202080087425.4A patent/CN114828851A/zh active Pending
- 2020-10-21 CA CA3158407A patent/CA3158407A1/en active Pending
- 2020-10-21 KR KR1020227016815A patent/KR20220104705A/ko active Search and Examination
- 2020-10-21 BR BR112022007651A patent/BR112022007651A2/pt unknown
- 2020-10-21 US US17/770,857 patent/US20220362165A1/en active Pending
- 2020-10-21 WO PCT/US2020/056559 patent/WO2021081022A1/en unknown
- 2020-10-21 TW TW109136539A patent/TW202128164A/zh unknown
- 2020-10-21 AU AU2020370073A patent/AU2020370073A1/en active Pending
- 2020-10-21 MX MX2022004827A patent/MX2022004827A/es unknown
- 2020-10-21 IL IL292405A patent/IL292405A/en unknown
- 2020-10-21 JP JP2022523672A patent/JP2023500606A/ja active Pending
- 2020-10-21 EP EP20879097.2A patent/EP4048268A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4048268A1 (en) | 2022-08-31 |
| AU2020370073A1 (en) | 2022-05-12 |
| US20220362165A1 (en) | 2022-11-17 |
| EP4048268A4 (en) | 2023-11-29 |
| TW202128164A (zh) | 2021-08-01 |
| MX2022004827A (es) | 2022-07-19 |
| IL292405A (en) | 2022-06-01 |
| CN114828851A (zh) | 2022-07-29 |
| KR20220104705A (ko) | 2022-07-26 |
| JP2023500606A (ja) | 2023-01-10 |
| WO2021081022A1 (en) | 2021-04-29 |
| CA3158407A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| BR112019002371A2 (pt) | composições farmacêuticas | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| BR112017025711A2 (pt) | ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras? | |
| CL2016002389A1 (es) | Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| BR112017016503A2 (pt) | conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo | |
| BR112015014969A2 (pt) | micromatriz para entrega de agente terapêutico e métodos de uso | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CO2018012506A2 (es) | Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre | |
| CL2021001027A1 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
| BR112015022408A2 (pt) | barras de limpeza que compreendem copolímeros anfifílicos super-hidrofílicos, e métodos para uso das mesmas | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil | |
| MX2019015888A (es) | Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70. | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| ZA202006415B (en) | Tetrabenazine transdermal delivery device | |
| BR112022007651A2 (pt) | Dispositivo de distribuição transdérmica de tetrabenazina | |
| BR112018008415A2 (pt) | formulações de liberação sustentada de anestésicos locais |